ClinicalTrials.gg
CompletedNCT02449902Updated Dec 14, 2015Results posted

TXV13-01 Estradiol Vaginal Softgel Capsules in Treating Postmenopausal Women With Symptoms of Vulvar and Vaginal Atrophy

A Phase 2 interventional study of Estradiol and placebo in Menopause, Vulvovaginal Atrophy and Painful Intercourse, sponsored by TherapeuticsMD. Completed at 1 site in United States. Open to female participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2015-12-14.

Sponsored by TherapeuticsMD · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
40 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 56 studies in Dyspareunia with a site in United States — 8 open to participants now, 9 under way, 1 of them phase 3. Dyspareunia · United States.

Enrollment
29th of 53
50 · median 60
Started
2013
with 3 others
Phase 2
7 of 56
1 open now
Registered
19th of 56
by date
Lead sponsor
2 of 56
TherapeuticsMD

Among the 56 studies in Dyspareunia with a site in United States, this one is the 29th largest by enrollment of the 53 interventional ones that give a count, is one of 4 that started in 2013, is one of 7 in phase 2, and was the 19th registered.

Dyspareunia

159 studies on the registry are indexed under Dyspareunia; 40 are open to participants now.

Browse Dyspareunia studies →

Open to participants now

8 of the 56 studies in Dyspareunia with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 28 Dyspareunia studies recruiting now, 11 (39%) set no upper age limit and 14 (50%) stop at 75 or younger; 1 takes children under 18; 8 take healthy volunteers.

This study: 40 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 56 studies in Dyspareunia with a site in United States, or all of them as a file.
02

Study summary

The study was designed to evaluate the efficacy and safety of TX-12-004-HR 10 μg in treating moderate to severe symptoms of vaginal atrophy associated with menopause after 14 days of treatment, and to estimate the effect size and variability of vulvovaginal atrophy endpoints. In addition, the systemic exposure to estradiol from single and multiple doses of TX-12-004-HR was to be investigated.

Read the detailed description

This study was a randomized, double-blind, placebo-controlled trial to evaluate safety and efficacy of the TX-12-004-HR formulation in reducing moderate to severe symptoms of vaginal atrophy associated with menopause and to investigate the systemic exposure to estradiol following once daily intravaginal administrations of TX-12-004-HR for 14 days.

Postmenopausal subjects who met the study entry criteria were randomized to one of two treatment groups (TX-12-004-HR or Placebo). During the Screening period subjects were asked to self-assess the symptoms of vulvar and/or vaginal atrophy, including vaginal dryness, vaginal and/or vulvar irritation/itching, dysuria, vaginal pain associated with sexual activity and vaginal bleeding associated with sexual activity. Subjects with at least one self-assessed moderate to severe symptom of vulvar and/or vaginal atrophy identified by the subject as being most bothersome to her were eligible to participate in the study.

03

Conditions studied

  • Menopause
  • Vulvovaginal Atrophy
  • Painful Intercourse
  • Dyspareunia

Browse trials for

Keywords

  • VVA
  • Postmenopausal
  • Painful Sex
04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Be a female between 40 and 75 years (at the time of randomization) who is willing to participate in the study, as documented by signing the form.
  2. Be a woman. Postmenopausal is defined with at least 12 months of spontaneous amenorrhea or 12 months post bilateral oophorectomy, with or without hysterectomy (documented by an operative report or patient reported). Women ≥ 60 years of age who have had a hysterectomy without bilateral oophorectomy prior to natural menopause are considered menopausal.
  3. Have a baseline evaluation requirements:

    • ≤5% superficial cells on vaginal smear cytology
    • Vaginal pH > 5.0
    • Estradiol level ≤ 50 pg/ml
    • At least one self-assessed moderate to severe symptom of vulvar and/or vaginal atrophy from the following list that is identified by the subject as being most bothersome to her:

      • Vaginal dryness
      • Vaginal pain associated with sexual activity
      • Vaginal and/or vulvar irritation/itching
      • Dysuria
      • Vaginal bleeding associated with sexual activity (absence vs. presence)
  4. Have a (BMI) less than or equal to 34 kg/m2. (BMI values should be rounded to the nearest integer [e.g., 34.4 rounds down to 34, while 26.5 rounds up to 27]).
  5. Be willing to abstain from using products (other than study medication) that contain estrogen throughout study participation.
  6. Be judged by the Principal Investigator or Sub-investigator as being in otherwise generally good health based on a pre-study medical evaluation performed within 28 days prior to the initial dose of study medication. The medical evaluation findings must include:

    • a normal or non- physical examination, including vital signs (sitting blood pressure, heart rate, respiratory rate and temperature).
    • a normal or non-clinically significant pelvic examination.
    • a mammogram that shows no sign of significant disease (can be performed within previous 9 months prior to initial dose of study medication). An acceptable mammogram is defined as a mammogram in which no masses or other findings are identified that is suspicious of . The site must obtain a copy of the official report for the subject's study file, and it must be verified that the mammogram itself is available if needed for additional assessment.
    • a normal or non-clinically significant clinical breast examination. An acceptable breast examination is defined as no masses or other findings identified that are suspicious of malignancy.
    • a normal Screening Papanicolaou ("Pap") smear (ASCUS with high risk- human papillomavirus (HPV) negative is acceptable).
    • within normal limits or non-clinically significant laboratory evaluation results
    • sitting systolic blood pressure ≤140 mmHg and diastolic blood pressure ≤90 mmHg at Screening. A subject may be taking up to two antihypertensive medications.
  7. Be willing to abstain from sexual activity and use of vaginal douching within 24 hours prior to screening and Visit 3 vaginal pH measurements.

Exclusion criteria

Exclusion Criteria:

  1. Be currently hospitalized.
  2. Have a history of thrombosis of deep veins or arteries or a thromboembolic disorder.
  3. Have a history of coronary artery or cerebrovascular disease.
  4. Have a history of liver or kidney dysfunction/disorder.
  5. Have a history of gallbladder dysfunction/disorders (e.g., cholangitis, cholecystitis), unless gallbladder has been removed.
  6. Have a history of diabetes, thyroid disease (subjects with diet-controlled diabetes, or controlled hypothyroid disease at Screening are not excluded), or any other endocrinological disease.
  7. Have a history of estrogen-dependent neoplasia.
  8. Have a history of atypical ductal hyperplasia of the breast.
  9. Have a history of undiagnosed vaginal bleeding.
  10. Have a vaginal infection requiring treatment
  11. Have any history of endometrial hyperplasia or uterine/endometrial, breast or ovarian cancer.
  12. Have any history of other within the last 5 years, with the exception of basal cell (excluded if within 1 year) or non-invasive squamous cell (excluded if within 1 year) carcinoma of the skin.
  13. Have a history of any other cardiovascular, hepatic, renal, pulmonary, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, psychological, or musculoskeletal disease or disorder that is in the opinion of the Principal Investigator or Medical Sub-Investigator.
  14. Have to estrogen therapy or allergy to the use of estradiol or any components of the drugs.
  15. Use 15 or more cigarettes per day.
  16. Have a history of drug and/or alcohol abuse within one year of start of study.
  17. Have used, within 28 days prior to Screening, or plan to use during the study, any prescription or over-the-counter (OTC) medications (including herbal products) that would be expected to interact with estradiol therapy.
  18. Use of any type of vaginal preparation (including lubricants and moisturizers) within 14 days prior to Screening.
  19. Have used estrogen alone or estrogen/progestin for any of the following time periods:

    • Vaginal hormonal products (rings, creams, gels) within 3 months prior to Screening.
    • Transdermal estrogen alone or estrogen/progestin products within 8 weeks prior to Screening.
    • Oral estrogen and/or progestin therapy within 8 weeks prior to Screening.
    • Progestational implants, estrogen or estrogen/progestational injectable drug therapy within 3 months prior to Screening.
    • Estrogen pellet therapy or progestational injectable drug therapy within 6 months prior to Screening.
    • Percutaneous estrogen lotions/gels within 8 weeks prior to Screening.
    • Oral, topical, vaginal, patch, implantable or injectable androgen therapy within 8 weeks prior to Screening.
  20. Have any reason which, in the opinion of the Principal Investigator or Medical Sub-Investigator, would prevent the subject from safely participating in the study or complying with protocol requirements.
  21. Have contraindication to any planned study procedure (e.g., blood collection).
  22. Have participated in another clinical trial within 30 days prior to screening, have received an investigational drug within the three months prior to the initial dose of study medication, or be likely to participate in a clinical trial or receive another investigational medication during the study.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
50 participants (actual)

Study arms

  • Active comparator
    Treatment 1

    Estradiol 10 μg vaginal softgel capsule

    Drug: Estradiol

  • Placebo comparator
    Treatment 2

    Placebo vaginal softgel capsule

    Drug: placebo

Interventions

  • 1 10 µg capsule inserted vaginally for 14 days.

    Also known as: 17β-estradiol

  • Drugplacebo

    1 placebo capsule inserted vaginally for 14 days.

06

What researchers measure

Primary outcomes

  1. Analysis of Change From Baseline to Day 15 in Maturation Index of the Vaginal Cell Type (Parabasal Cells)

    Time frame: Baseline to 15 days post-treatment

  2. Analysis of Change From Baseline to Day 15 in Maturation Index of the Vaginal Cell Type (Superficial Cells)

    Time frame: Baseline to 15 days post-treatment

  3. Analysis of Change From Baseline to Day 15 in Maturation Index of the Vaginal Cell Type (Intermediate Cells)

    Time frame: Baseline to 15 days post-treatment

  4. Analysis of Change From Baseline to Day 15 in Vaginal pH

    Time frame: Baseline to 15 days post-treatment

  5. Analysis of Change From Baseline to Day 15 in Severity of the Most Bothersome Vulvar and Vaginal Atrophy (VVA) Symptom

    The severity of the most bothersome VVA symptom was self-assessed by each subject using a VVA questionnaire. The questionnaire has a 4-point scoring scale with: None=0, Mild=1, Moderate=2, and Severe=3. The lower the score, the least bothersome it is to the subject.

    Time frame: Baseline to 15 days post-treatment

  6. Analysis of Change From Baseline to Day 15 in Vaginal Bleeding Associated With Sexual Activity

    Total number (N=10) of participants analyzed within each treatment group who were sexually active at both Baseline and Day 15 and provided a response at both visits.

    Time frame: Baseline to 15 days post-treatment

  7. Analysis of Change From Baseline to Day 15 in Investigator Assessment of the Vaginal Mucosa (Assessment of Vaginal Color)

    Outcome was measured by using a severity scale. No Atrophy is pink in color (0). Mild atrophy is lighter in color (1). Moderate atrophy is pale in color (2). Severe atrophy is transparent, either no color or inflamed (3).

    Time frame: Baseline to 15 days post-treatment

  8. Analysis of Change From Baseline to Day 15 in Investigator Assessment of the Vaginal Mucosa (Assessment of Vaginal Epithelial Integrity)

    Outcome was measured by using a severity scale. No Atrophy=normal(0). Mild atrophy=vaginal surface bleeds with scraping(1). Moderate atrophy=vaginal surface bleeds with light contact(2). Severe atrophy=vaginal surface has petechiae before contact and bleeds with light contact(3).

    Time frame: Baseline to 15 days post-treatment

  9. Change From Baseline to Day 15 in Investigator Assessment of the Vaginal Mucosa (Assessment of Vaginal Epithelial Surface Thickness)

    Outcome was measured by using a severity scale. No Atrophy has rogation and elasticity of vault(0). Mild atrophy has poor rogation with some elasticity noted of vaginal vault(1). Moderate atrophy is smooth, some elasticity of vaginal vault(2). Severe atrophy is smooth, no elasticity, constriction of the upper one third of vagina or loss of vaginal tone (cystocele and rectocele)(3).

    Time frame: Baseline to 15 days post-treatment

  10. Analysis of Change From Baseline to Day 15 in Investigator Assessment of the Vaginal Mucosa (Assessment of Vaginal Secretions)

    Outcome was measured by using a severity scale. No Atrophy has normal clear secretions noted on vaginal walls(0). Mild atrophy has superficial coating of secretions, difficulty with speculum insertion(1). Moderate atrophy is scant not covering the entire vaginal vault, may need lubrication with speculum insertion to prevent pain(2). Severe atrophy has none, inflamed, ulceration noted, need lubrication with speculum insertion to prevent pain(3).

    Time frame: Baseline to 15 days post-treatment

07

Results

Posted Dec 14, 2015

Participant flow

Participant flow — Overall Study
MilestoneTX-12-004-HR 10μgPlacebo
Started2426
Completed2424
Not completed02
Withdrew: Adverse event01
Withdrew: Withdrawal by subject01

Outcome measures

PrimaryAnalysis of Change From Baseline to Day 15 in Maturation Index of the Vaginal Cell Type (Parabasal Cells)
Time frame:
Baseline to 15 days post-treatment
Reported as:
Least squares mean · Percentage of Parabasal Cells
Analysis of Change From Baseline to Day 15 in Maturation Index of the Vaginal Cell Type (Parabasal Cells)
Percentage of Parabasal CellsTX-12-004-HR 10μgPlacebo
Analysis of Change From Baseline to Day 15 in Maturation Index of the Vaginal Cell Type (Parabasal Cells)-54.4 ± 4.6-4.8 ± 4.6
Statistical analysis
  • TX-12-004-HR 10μg vs Placebo · ANCOVA · p = <0.0001
PrimaryAnalysis of Change From Baseline to Day 15 in Maturation Index of the Vaginal Cell Type (Superficial Cells)
Time frame:
Baseline to 15 days post-treatment
Reported as:
Least squares mean · Percentage of Superficial Cells
Analysis of Change From Baseline to Day 15 in Maturation Index of the Vaginal Cell Type (Superficial Cells)
Percentage of Superficial CellsTX-12-004-HR 10μgPlacebo
Analysis of Change From Baseline to Day 15 in Maturation Index of the Vaginal Cell Type (Superficial Cells)35.2 ± 4.78.8 ± 4.7
Statistical analysis
  • TX-12-004-HR 10μg vs Placebo · ANOVA · p = 0.0002
PrimaryAnalysis of Change From Baseline to Day 15 in Maturation Index of the Vaginal Cell Type (Intermediate Cells)
Time frame:
Baseline to 15 days post-treatment
Reported as:
Least squares mean · Percentage of Intermediate Cells
Analysis of Change From Baseline to Day 15 in Maturation Index of the Vaginal Cell Type (Intermediate Cells)
Percentage of Intermediate CellsTX-12-004-HR 10μgPlacebo
Analysis of Change From Baseline to Day 15 in Maturation Index of the Vaginal Cell Type (Intermediate Cells)18.7 ± 4.7-3.5 ± 4.7
Statistical analysis
  • TX-12-004-HR 10μg vs Placebo · ANCOVA · p = 0.0017
PrimaryAnalysis of Change From Baseline to Day 15 in Vaginal pH
Time frame:
Baseline to 15 days post-treatment
Reported as:
Least squares mean · pH
Analysis of Change From Baseline to Day 15 in Vaginal pH
pHTX-12-004-HR 10μgPlacebo
Analysis of Change From Baseline to Day 15 in Vaginal pH-0.97 ± 0.1-0.34 ± 0.1
Statistical analysis
  • TX-12-004-HR 10μg vs Placebo · ANCOVA · p = 0.0002
PrimaryAnalysis of Change From Baseline to Day 15 in Severity of the Most Bothersome Vulvar and Vaginal Atrophy (VVA) Symptom

The severity of the most bothersome VVA symptom was self-assessed by each subject using a VVA questionnaire. The questionnaire has a 4-point scoring scale with: None=0, Mild=1, Moderate=2, and Severe=3. The lower the score, the least bothersome it is to the subject.

Time frame:
Baseline to 15 days post-treatment
Reported as:
Least squares mean · units on a scale
Analysis of Change From Baseline to Day 15 in Severity of the Most Bothersome Vulvar and Vaginal Atrophy (VVA) Symptom
units on a scaleTX-12-004-HR 10μgPlacebo
Analysis of Change From Baseline to Day 15 in Severity of the Most Bothersome Vulvar and Vaginal Atrophy (VVA) Symptom-1.043 ± 0.2-1.042 ± 0.2
Statistical analysis
  • TX-12-004-HR 10μg vs Placebo · ANOVA · p = 0.9951
PrimaryAnalysis of Change From Baseline to Day 15 in Vaginal Bleeding Associated With Sexual Activity

Total number (N=10) of participants analyzed within each treatment group who were sexually active at both Baseline and Day 15 and provided a response at both visits.

Time frame:
Baseline to 15 days post-treatment
Reported as:
Number · participants
Analysis of Change From Baseline to Day 15 in Vaginal Bleeding Associated With Sexual Activity
participantsTX-12-004-HR 10μgPlacebo
Bleeding/ No Bleeding (Success)21
Bleeding/ Bleeding (Failure)03
No Bleeding/ Bleeding (Failure)01
No Bleeding/ No Bleeding (No Change)85
Statistical analysis
  • TX-12-004-HR 10μg vs Placebo · Fisher Exact · p = 0.1429
PrimaryAnalysis of Change From Baseline to Day 15 in Investigator Assessment of the Vaginal Mucosa (Assessment of Vaginal Color)

Outcome was measured by using a severity scale. No Atrophy is pink in color (0). Mild atrophy is lighter in color (1). Moderate atrophy is pale in color (2). Severe atrophy is transparent, either no color or inflamed (3).

Time frame:
Baseline to 15 days post-treatment
Reported as:
Least squares mean · units on a scale
Analysis of Change From Baseline to Day 15 in Investigator Assessment of the Vaginal Mucosa (Assessment of Vaginal Color)
units on a scaleTX-12-004-HR 10μgPlacebo
Analysis of Change From Baseline to Day 15 in Investigator Assessment of the Vaginal Mucosa (Assessment of Vaginal Color)-0.199 ± 0.1-0.009 ± 0.1
Statistical analysis
  • TX-12-004-HR 10μg vs Placebo · ANCOVA · p = 0.1945
PrimaryAnalysis of Change From Baseline to Day 15 in Investigator Assessment of the Vaginal Mucosa (Assessment of Vaginal Epithelial Integrity)

Outcome was measured by using a severity scale. No Atrophy=normal(0). Mild atrophy=vaginal surface bleeds with scraping(1). Moderate atrophy=vaginal surface bleeds with light contact(2). Severe atrophy=vaginal surface has petechiae before contact and bleeds with light contact(3).

Time frame:
Baseline to 15 days post-treatment
Reported as:
Least squares mean · units on a scale
Analysis of Change From Baseline to Day 15 in Investigator Assessment of the Vaginal Mucosa (Assessment of Vaginal Epithelial Integrity)
units on a scaleTX-12-004-HR 10μgPlacebo
Analysis of Change From Baseline to Day 15 in Investigator Assessment of the Vaginal Mucosa (Assessment of Vaginal Epithelial Integrity)-0.342 ± 0.10.176 ± 0.1
Statistical analysis
  • TX-12-004-HR 10μg vs Placebo · ANCOVA · p = 0.0001
PrimaryChange From Baseline to Day 15 in Investigator Assessment of the Vaginal Mucosa (Assessment of Vaginal Epithelial Surface Thickness)

Outcome was measured by using a severity scale. No Atrophy has rogation and elasticity of vault(0). Mild atrophy has poor rogation with some elasticity noted of vaginal vault(1). Moderate atrophy is smooth, some elasticity of vaginal vault(2). Severe atrophy is smooth, no elasticity, constriction of the upper one third of vagina or loss of vaginal tone (cystocele and rectocele)(3).

Time frame:
Baseline to 15 days post-treatment
Reported as:
Least squares mean · units on a scale
Change From Baseline to Day 15 in Investigator Assessment of the Vaginal Mucosa (Assessment of Vaginal Epithelial Surface Thickness)
units on a scaleTreatment 1Treatment 2
Change From Baseline to Day 15 in Investigator Assessment of the Vaginal Mucosa (Assessment of Vaginal Epithelial Surface Thickness)-0.034 ± 0.1-0.133 ± 0.1
Statistical analysis
  • Treatment 1 vs Treatment 2 · ANCOVA · p = 0.1820
PrimaryAnalysis of Change From Baseline to Day 15 in Investigator Assessment of the Vaginal Mucosa (Assessment of Vaginal Secretions)

Outcome was measured by using a severity scale. No Atrophy has normal clear secretions noted on vaginal walls(0). Mild atrophy has superficial coating of secretions, difficulty with speculum insertion(1). Moderate atrophy is scant not covering the entire vaginal vault, may need lubrication with speculum insertion to prevent pain(2). Severe atrophy has none, inflamed, ulceration noted, need lubrication with speculum insertion to prevent pain(3).

Time frame:
Baseline to 15 days post-treatment
Reported as:
Least squares mean · units on a scale
Analysis of Change From Baseline to Day 15 in Investigator Assessment of the Vaginal Mucosa (Assessment of Vaginal Secretions)
units on a scaleTX-12-004-HR 10μgPlacebo
Analysis of Change From Baseline to Day 15 in Investigator Assessment of the Vaginal Mucosa (Assessment of Vaginal Secretions)-0.643 ± 0.1-0.274 ± 0.1
Statistical analysis
  • TX-12-004-HR 10μg vs Placebo · ANCOVA · p = 0.0401

Adverse events

Collected over Adverse events were collected for 14 days (study duration). Subjects with AEs that were ongoing at study completion or study withdrawal were followed until resolution or for 30 days after the last dose of study medication.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
TX-12-004-HR—0/24 (0%)13/24 (54.2%)
Placebo—0/26 (0%)4/26 (15.4%)
Most frequent other events
Showing 10 of 12
Most frequent other events
EventTX-12-004-HRPlacebo
Vaginal dysplasiaReproductive system and breast disorders4/240/26
Hot flushReproductive system and breast disorders2/240/26
Vaginal haemorrhageReproductive system and breast disorders0/242/26
Blood pressure increasedBlood and lymphatic system disorders1/240/26
Eye ContusionEye disorders1/240/26
NephrolithiasisRenal and urinary disorders1/240/26
Vulvovaginal burning sensationReproductive system and breast disorders1/240/26
Vulvovaginal pruritusReproductive system and breast disorders1/240/26
Vaginal dischargeReproductive system and breast disorders1/240/26
Vulvovaginal painReproductive system and breast disorders1/240/26

Baseline characteristics

Age, Continuous
Age, Continuous(years)Estradiol 10 μg Daily for 14 DaysPlacebo Daily for 14 DaysTotal
Mean62.4 ± 5.762.3 ± 7.062.3 ± 6.4
Sex/Gender, Customized
Sex/Gender, Customized(participants)Estradiol 10 μg Daily for 14 DaysPlacebo Daily for 14 DaysTotal
Female242650
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Estradiol 10 μg Daily for 14 DaysPlacebo Daily for 14 DaysTotal
American Indian or Alaska Native000
Asian101
Native Hawaiian or Other Pacific Islander000
Black or African American224
White212445
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Estradiol 10 μg Daily for 14 DaysPlacebo Daily for 14 DaysTotal
United States242650
BMI (kg/m^2)
BMI (kg/m^2)(kg/m^2)Estradiol 10 μg Daily for 14 DaysPlacebo Daily for 14 DaysTotal
Mean26.4 ± 3.927.2 ± 3.326.8 ± 3.6
08

Study locations

1 site
  • Avail Clinical Research
    DeLand, Florida 32720, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2013, a primary completion of Sep 2013 and a completion of Sep 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2015, 2 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 18, 2015
First posted
May 20, 2015
Start
Jul 2013
Primary completionActual
Sep 2013
CompletionActual
Sep 2013
Results first posted
Dec 14, 2015
Last update
Dec 14, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 14, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02449902
Lead sponsor
TherapeuticsMD
Responsible party
Sponsor
First posted
May 20, 2015
Start date
Jul 2013
Primary completion
Sep 2013
Completion
Sep 2013
Results posted
Dec 14, 2015
Last update
Dec 14, 2015

Study contacts

Shelli Graham, PhD
study director · TherapeuticsMD

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Estradiol

Start the discussion